Unfortunately, most of the patients with B-ALL eventually relapse after CD22 CAR T-cell therapy [31] due to reduced or diminished CD22 expression levels in B-cell lymphoblasts (immature B cells). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.